Latest Pharmaceutics Stories

Halo Pharma And Altus Formulation Announce New Formal Collaboration

2013-05-14 12:30:40

MONTREAL, May 14, 2013 /PRNewswire/ -- Halo Pharma today announced that it has taken a minority ownership position in, and established a formal collaboration with, the drug formulation and development company Altus Formulation Inc. Altus uses proprietary technologies and approaches to solve pharmaceutical formulation and delivery problems. Halo is focused on satisfying the pharmaceutical client's development and manufacturing needs, whether those needs are straightforward or...

Contract Research Organization WCCT Global Awarded the 2013 Cypress Award for the Second Consecutive Year for Work in Clinical Research

2013-05-09 23:50:14

WCCT Global, a contract research organization headquartered in Southern California, has been awarded the 2013 Cypress Award. Costa Mesa, CA (PRWEB) May 08, 2013 Contract research organization WCCT Global has been awarded the 2013 Cypress Award for the second consecutive year. This has been awarded due to research work that WCCT Global has conducted over the past year and the growth within the organization. For 2013, only 1.4% of all who received this award have received this for two...

Alimera Sciences To Release First Quarter Fiscal Year 2013 Financial Results

2013-05-03 12:25:30

ATLANTA, May 3, 2013 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its first quarter fiscal year 2013 financial results after the market close on Thursday, May 9, 2013. An investor conference call will follow on the same day at 4:30 p.m. ET. The conference call will be hosted by Dan Myers,...

Ambrx Initiates Collaboration with Bristol-Myers Squibb for Discovery, Development of Next-Generation Antibody Drug Conjugates

2013-05-03 08:25:40

SAN DIEGO, May 3, 2013 /PRNewswire/ -- Ambrx today entered into a collaboration agreement with Bristol-Myers Squibb (NYSE: BMY) for the discovery and development of novel antibody drug conjugates using Ambrx's protein medicinal chemistry technology. Under terms of the agreement, Ambrx will receive an upfront payment of $15 million, funding for discovery and research activities, and potential development, regulatory and sales based milestone payments of up to $97 million per product...

qPCR Assay, PDD & Benchtop Automation 2013 Market Trends

2013-05-01 08:26:34

ReportsnReports.com offers 2013 market research reports on trends in qPCR Assay, phenotypic drug discovery, benchtop automation and mass spectrometry (MS)-based screening assays. DALLAS, May 1, 2013 /PRNewswire-iReach/ -- qPCR Assay Trends 2013, Phenotypic Drug Discovery Trends 2013, Benchtop Automation Trends 2013 and Mass Spec-Based Screening Assay Trends 2013 are new reports available with ReportsnReports.com (Photo: http://photos.prnewswire.com/prnh/20130501/CG04491)...

Vatsala Naageshwaran of Absorption Systems to Present at Disso 2013 International Conference in Mumbai, India on May 3rd

2013-04-30 12:27:51

EXTON, Pa., April 30, 2013 /PRNewswire/ -- Absorption Systems, a global leader in preclinical contract testing of drugs, biologics, and medical devices, is pleased to announce that Vatsala Naageshwaran, Associate Director of Scientific Operations, will present a talk at the Disso 2013 Conference on May 3(rd) in Mumbai, India. The title of her presentation is "Permeability classification of highly variable drugs using the in vitro Caco-2 assay." The symposium, convened under the...

Henri A. Termeer Joins Moderna Therapeutics Board Of Directors

2013-04-30 08:33:46

CAMBRIDGE, Mass., April 30, 2013 /PRNewswire/ -- Moderna Therapeutics, the pioneering company developing messenger RNA therapeutics(TM)--a revolutionary new treatment modality to enable the in vivo production of therapeutic proteins--announced today that Henri A. Termeer, Genzyme's retired chairman, president, and CEO, has joined Moderna's board of directors. Over nearly 30 years at Genzyme, Termeer built one of the world's most innovative and commercially successful biotechnology...

Reliable Biopharmaceutical Corporation Announces Facility Expansion for High Purity Ingredients

2013-04-22 23:03:51

Reliable Biopharmaceutical Corporation (RBC) announced today that it has invested several million dollars into its High Purity production suites. These investments will nearly triple the production capacity in its High Purity Ingredients (HPI) line. St. Louis, Missouri (PRWEB) April 22, 2013 Reliable Biopharmaceutical Corporation (RBC) announced today that it has invested several million dollars into its High Purity production suites. These investments will nearly triple the production...

New PAREXEL Report Defines The Next Generation Of Strategic Partnerships Between CROs And Biopharmaceutical Industry

2013-04-22 08:29:00

Majority of biopharma executives believe Strategic Partnerships positively impact their engagement with CROs BOSTON, April 22, 2013 /PRNewswire/ -- PAREXEL International (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today released a new research report called Strategic Partnerships 2013 at the 22(nd) Annual Partnerships in Clinical Trials Conference in Orlando, FL. The report is the first to explore the current outsourcing landscape and the value Strategic...

DSM and DecImmune Therapeutics Sign Agreement to Develop N2 Pathway Blocking Antibody

2013-04-22 04:21:07

PARSIPPANY, N.J., April 22, 2013 /PRNewswire/ -- DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE, Euronext: DSM KON), announced today that it has signed an agreement with venture capital funded DecImmune Therapeutics of Cambridge, Massachusetts, USA The agreement covers the initiation of development activities by DSM for DecImmune's lead monoclonal antibody program. The initial development will be performed at DSM Biologics'...